Fundamental Analysis of Amneal Pharmaceuticals Inc. - Growth / Value Index
AMRX - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.778
Price to Book Ratio of 18.63 suggesting that it is very expensive
Book Value in last 3 years is trending down
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -10.74 | -14.11 | -80.59 % | |
| Price to Book | 18.39 | 59.93 | 985.31 % | -124.53 |
| Price to Sales | 0.584 | 0.495 | 7.85 % | |
| Enterprise Value to EBITDA Multiple | 28.03 | -3137.02 | -23520.49 % |
AMRX - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 9.21
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -171.16 | -424.61 | -500.99 % | 0 |
| Return On Asset | -3.78 | -2.42 | 29.30 % | -2.65 |
| Net Profit Margin | -5.43 | -3.51 | 40.28 % | -13.90 |
| Operating Profit Margin | 6.38 | -0.0475 | 98.89 % | -1.63 |
| EBITDA Margin | 6.38 | -0.0475 | -100.38 % | -1.63 |
Highlights
| Market Cap | 2077.22 M |
| Enterprise Value | 4461.75 M |
| Price/Book TTM | 18.39 |
| Outstanding Share | 308651 K |
| Float/ Outstanding Share | 42.97% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | 0.817 |
| Sloan Ratio | -0.124 |
| Peter Lynch Fair Value | 0 |
AMRX - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 2495.26 M | 8.20 % | 6.84 % |
| Gross Profit | 880439 K | 4.57 % | 25.41 % |
| EBITDA | 159179 K | 100.41 % | 175.71 % |
| Net Profit | -135576.00 K | 35.38 % | 7.10 % |
| EPS | -0.627 | 44.62 % | NA |
AMRX - Stability Highlights
Stability Analysis
Decreasing debt with Increasing revenue
Tsr Stability Index - Very Poor Score of 5.00
Altman Z Score of 0.822 suggest high risk
Company has high debt burden
Interest Coverage of -1.09
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 125.17 | 754.01 % | -38.81 |
| Cash Ratio | 0.108 | 213.37 % | |
| Quick Ratio | 0.941 | -19.62 % | 0.970 |
| Shareholders Equity | 0.570 | -88.24 % | |
| Debt to EBITDA | -2175.81 | -22307.23 % |
Historical Valuation Ratios of Amneal Pharmaceuticals Inc.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Amneal Pharmaceuticals Inc.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Amneal Pharmaceuticals Inc.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Amneal Pharmaceuticals Inc.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)